[Systemic thrombolysis using streptokinase. Experiences at the Civic Hospital of Lugano in the framework of the ISIS-2 study].

Abstract

With a small group of Swiss hospitals we had an opportunity of participating in ISIS-2, the major study on thrombolysis in acute myocardial infarction. Experience with our microcosm (Ospedale Civico Lugano) was compared with the macrocosm of the results of ISIS-2 in 17,187 randomized patients (in brackets). Mortality was 5.1% (7.8%) in our streptokinase group and 15.8% (12.8%) in our placebo group. In the ISIS-2 study the combination of thrombolytic therapy with streptokinase, and of antiplatelet therapy with aspirin, showed a reduction of approximately one third in acute mortality of myocardial infarction, stroke and reinfarction. Our experience confirms the reduced incidence of allergic side effects (3.5%), major bleeding (0.3%) and minor bleeding (2.9%) during or after thrombolytic therapy.

• Authors: T Moccetti, M Rezzonico, F Clara, A Riva, F Tanzi, M Genoni, R Malacrida
• Journal: Schweizerische medizinische Wochenschrift (Schweiz Med Wochenschr) Vol. 118 Issue 46 Pg. 1702-5 (Nov 19 1988) ISSN: 0036-7672 [Print] Switzerland
• Vernacular Title: Systemische Thrombolyse mit Streptokinase. Erfahrungen am Ospedale Civico Lugano im Rahmen der ISIS-2-Studie.
• PMID: 3212423 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Streptokinase
• Aspirin

Topics

• Administration, Oral
• Aspirin (therapeutic use)
• Double-Blind Method
• Female
• Humans
• Infusions, Intravenous
• Male
• Myocardial Infarction (drug therapy, mortality)
• Streptokinase (administration & dosage, adverse effects, therapeutic use)
• Switzerland